The Oncotype DX® test provides significant value in clinical practice

For node-positive, early-stage HR+HER2- breast cancer patients

 

Challenging Node-Positive Cases - Drs. Jeremy Force and Christy Russell

 


The Oncotype DX Breast Recurrence Score® result is predictive of chemotherapy benefit in your postmenopausal patients with HR+, HER2-, node-positive (1-3 positive nodes), early-stage, invasive breast cancer as demonstrated by the SWOG-8814 study.1 Data from SWOG-8814 and the RxPONDER randomized prospective trial show that a substantial proportion of these patients can be spared chemotherapy.1-7



CT benefit expressed in percentage points based on probability of distant recurrence (N0) or distant recurrence-free interval (N1) with/without CT at 5 years. No CT benefit is considered for an absolute benefit <1%.
*The benefit of chemotherapy for premenopausal N1 patients with RS® results 26-100 has not been formally assessed in a randomized study. The benefit derived from chemotherapy was significant for RS® results 0-13 and 14-25 in the RxPONDER study and it is inferred to be substantial for patients with RS® 26-100.

 
How can the Oncotype DX test help guide treatment decisions?

SWOG 8814 established the Oncotype DX® test as predictive of CT benefit in node-positive postmenopausal patients1. RxPONDER study results added to the findings of SWOG 8814 by providing a refined estimate of CT benefit in N1 patients with the following results6-7:

  • N1 postmenopausal patients with Recurrence Score® results 0-25 can be spared chemotherapy regardless of the number of affected nodes, tumour grade or size.6-7
  • N1 premenopausal patients with Recurrence Score results 0-25 derive a 2.4% benefit from chemotherapy based on distant recurrence-free interval at 5 years.6-7
 

Use of the Oncotype DX test may reduce the risk of overtreatment in node-positive HR+HER2- early stage breast cancer1,6-7

Node-positive patients are believed to have higher clinical risk and worse prognosis if not treated with chemotherapy10. Average chemotherapy treatment rates without genomic testing are in the range of 70% for this patient population8-9. RxPONDER demonstrated that many of these patients may be overtreated6-7, and the Oncotype DX test can help make informed treatment decisions.


N1

Nodal status, despite being of prognostic value, does not predict the Recurrence Score result and the underlying tumour biology4


Overall, 566,438 tumour specimens with known nodal status were examined by the Genomic Health laboratory (now Exact Sciences) from February 2004 to August 20174


CLINICAL UTILITY OF THE ONCOTYPE DX ASSAY

 

In summary, adjuvant chemotherapy may be guided with the Oncotype DX test to identify the majority of node-positive patients (with up to 3 positive nodes) who will not benefit from the addition of chemotherapy.1,6-7

 


Read more on clinical evidence in node-positive patients

The Oncotype DX Breast Recurrence Score* test should be used for:

  • All patients for whom chemotherapy can potentially be spared
  • All patients for whom chemotherapy can potentially be life-saving

*For early stage, HR+, HER2- patients with up to 3 involved nodes

 
ABBREVIATIONS

CT=chemotherapy;
HER2–=human epidermal growth factor receptor 2 negative;
HR+=hormone receptor positive;
LN=lymph node;
N+=node-positive;
N0=node-negative;
N1mi=node-positive with micrometastases;
N1=1–3 positive nodes;
RS=Recurrence Score result

 
REFERENCES
  1. Albain et al. Lancet Oncol. 2010.
  2. Stemmer et al. NPJ Breast Cancer. 2017.
  3. Hortobagyi et al. SABCS. 2018.
  4. Bello et al. Ann Surg Onc. 2018.
  5. Nitz et al. Breast Cancer Res Treat. 2017.
  6. Kalinsky et al, SABCS 2021 GS2-07
  7. Kalinsky et al. N Eng J Med. 2021
  8. Allemani et al. Int J Cancer. 2013.
  9. Zhang et al. Breast Can Res Treat. 2020.
  10. Tonellotto et al. Eur J Breast Health. 2019.
  11. Chen et al. Ann Surg Onc. 2007.
 
Making cancer care smarter.™